Compounded semaglutide is a semaglutide injection prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk A/S. It uses the same active molecule found in Ozempic and Wegovy, but the finished product is not FDA-approved, is usually combined with an additive like vitamin B12 or glycine, and is produced under a different regulatory pathway. That pathway narrowed sharply after the FDA declared the semaglutide shortage resolved on February 21, 2025, closing the door that 503A and 503B compounders had been pouring through since 2022.1
This guide covers what compounded semaglutide is, how it differs from Ozempic and Wegovy, why pharmacies made it, what the April and May 2025 FDA deadlines changed, and what the safety data shows. It does not cover individual dosing titration (see our GLP-1 dosing guide), insurance appeals for Wegovy coverage, side-effect management protocols, or provider-specific telehealth recommendations. For the head-to-head on active molecules, see our semaglutide vs. tirzepatide comparison. Clinical decisions about GLP-1 therapy should be made with a licensed prescriber.
Key Takeaways
- Compounded semaglutide shares the same active molecule as Ozempic and Wegovy, a GLP-1 receptor agonist, but the finished product is made by a compounding pharmacy and is not FDA-approved.2
- The FDA declared the semaglutide shortage resolved on February 21, 2025. 503A pharmacies had until April 22, 2025 and 503B outsourcing facilities until May 22, 2025 to stop compounding copies.1
- On April 24, 2025, a federal court denied the Outsourcing Facilities Association's preliminary-injunction motion, letting the FDA's timeline stand.1
- The FDA has documented dosing errors at five to 20 times the intended dose, with adverse events including acute pancreatitis and gallstones.3
- Novo Nordisk testing of market samples has reported impurities up to 33% and some samples containing zero measurable active ingredient.4
- A peer-reviewed 2025 review in the American Journal of Managed Care concludes compounded semaglutide can serve a legitimate need when produced under full regulations, while noting current quality controls are uneven.5
What is compounded semaglutide?
Semaglutide is a once-weekly injectable peptide that acts on the glucagon-like peptide-1 (GLP-1) receptor. Novo Nordisk markets it under three brand names: Ozempic (approved for Type 2 diabetes on December 5, 2017, NDA 209637), Wegovy (approved for chronic weight management on June 4, 2021, NDA 215256), and oral Rybelsus. Both injectables are manufactured at Novo Nordisk facilities and sold as prefilled pens.2
Compounded semaglutide is a different pathway. A compounding pharmacy buys the active pharmaceutical ingredient from a bulk-drug-substance supplier, then prepares a finished injectable on its own premises. Two categories operate in the US:
- 503A pharmacies are state-licensed, prepare medications for individual patient-specific prescriptions, and are not FDA-registered.
- 503B outsourcing facilities are FDA-registered, can produce larger batches without patient-specific prescriptions, and operate under tighter federal oversight.
Neither category submits its finished semaglutide product for FDA review. That is the structural difference between "compounded semaglutide" and the semaglutide sold by Novo Nordisk.1
How is compounded semaglutide different from Ozempic and Wegovy?
The active molecule is the same. Almost everything else is different:
| Dimension | Ozempic / Wegovy (Brand) | Compounded Semaglutide |
|---|---|---|
| Manufacturer | Novo Nordisk A/S | Licensed 503A or 503B pharmacy |
| FDA approval | Yes (Ozempic 2017, Wegovy 2021)2 | No, finished product is not FDA-approved |
| Active ingredient | Semaglutide base | Semaglutide base or, in some products, semaglutide sodium or acetate, salt forms the FDA has flagged as unapproved active ingredients3 |
| Typical additives | Inactive excipients on the FDA label | Vitamin B12, glycine, pyridoxine (B6), or niacinamide |
| Potency testing | Batch-tested to FDA-approved specifications | Pharmacy-dependent; Novo Nordisk testing reported impurities up to 33% and some samples with zero active ingredient4 |
| Regulatory status in 2026 | Actively marketed | Shortage-based enforcement discretion ended May 22, 2025; patient-specific compounding with additives continues under a contested legal theory1 |
| Typical monthly price | Ozempic list around $997; Wegovy list around $1,349 | $150 – $400 reported, varies widely by provider |
Comparison as of April 20, 2026. Compounded pricing varies widely by provider; confirm any price directly.
What did the 2025 FDA deadlines change?
Compounders were legally allowed to produce copies of semaglutide while it sat on the FDA shortage list from 2022 to 2025. Demand had outrun Novo Nordisk's manufacturing capacity, and under federal law both 503A and 503B compounders can prepare copies of a drug in shortage. That window let telehealth companies build large patient panels around monthly pricing of $150 to $400, often the difference between starting therapy and not starting at all.5
On February 21, 2025, the FDA declared the shortage resolved after concluding Novo Nordisk's supply met or exceeded demand. The agency set transition windows so patients were not cut off overnight:1
- 503A state-licensed pharmacies: compounding allowed until April 22, 2025.
- 503B outsourcing facilities: compounding allowed until May 22, 2025.
After those dates, neither category may compound a product that is "essentially a copy" of a commercially available drug. The Outsourcing Facilities Association sued on February 24, 2025 to block the FDA's decision. On April 24, 2025, the US District Court for the Northern District of Texas denied the preliminary-injunction motion in Outsourcing Facilities Association v. FDA, letting the agency's timeline stand.1
Enforcement has escalated since. The FDA issued more than 55 warning letters to online compounded-GLP-1 sellers on September 16, 2025, and announced further restrictions on the active pharmaceutical ingredients used in non-FDA-approved compounded products on February 6, 2026. Novo Nordisk has pursued parallel civil litigation, including a February 9, 2026 patent-infringement lawsuit against Hims & Hers Health, Inc. with a reported 132 federal complaints filed across 40 states as of early 2026.4
What does the safety data actually show?
We organize the compounded-GLP-1 safety picture using a Three-Tier Evidence Model: Tier 1 is regulatory adverse-event reporting, Tier 2 is manufacturer testing claims, and Tier 3 is peer-reviewed synthesis. Each tier answers a different question and carries a different bias profile. We apply the same structure across this site's GLP-1 coverage so readers can compare sources at a glance.
Tier 1, Regulatory reporting. The FDA alert on compounded semaglutide, last updated July 26, 2024, describes reports of adverse events "some requiring hospitalization" tied to dosing errors in which patients administered five to 20 times the intended dose. Most reports involved patients drawing doses from a multiple-dose vial with a U-100 insulin syringe and miscounting units, a 5-unit intended dose becoming 25 or 100. Symptoms reported include nausea, vomiting, abdominal pain, dehydration, fainting, acute pancreatitis, and gallstones. The alert also flags that some compounded products use semaglutide sodium or semaglutide acetate, salt forms the FDA says are "different active ingredients" than the base form in approved drugs.3
Tier 2, Manufacturer testing. Novo Nordisk has published testing results on market samples claiming some showed impurities up to 33%, some contained zero measurable active ingredient, and some contained contaminants including trace metals, residual solvents, and the research peptide BPC-157. These are Novo Nordisk's own findings, and readers should weigh them alongside the fact that the company is the party most threatened commercially by the compounded market, while noting that the independent FDA alert flags consistent concerns.4
Tier 3, Peer-reviewed literature. A 2025 narrative review in the American Journal of Managed Care concludes that compounded semaglutide produced under full federal and state regulations "can fill an important need" in the market, while cautioning that much of the market "may lack the quality controls historically seen with compounded formulations" and that "batches of fraudulent products" have been documented internationally.5
None of these sources says compounded semaglutide is categorically dangerous. What they say, together, is that outcomes depend heavily on which pharmacy prepared the product, what salt form and additive it contains, how the dose is measured, and whether the seller is operating legally. That variability is the central concern, not compounding itself.
The class-level adverse reaction profile of semaglutide itself, gastrointestinal reactions during escalation plus the serious reactions in the FDA label, is the same for compounded preparations because the active molecule is the same. For the full rate tables from the Wegovy and Ozempic labels, see our semaglutide side effects breakdown.
Questions worth asking before you pick a compounder
Compounded semaglutide quality is pharmacy-specific. Before enrolling with any compounder, telehealth or local, ask:
- Is this pharmacy 503A or 503B? 503B facilities are FDA-registered and inspected; 503A pharmacies are state-regulated only.
- Can you show me a current state board of pharmacy license? Verify the license number on the state board registry yourself.
- What salt form of semaglutide is used? The FDA has warned against semaglutide sodium and semaglutide acetate.3
- What additive is in this formulation, and why? B12, glycine, pyridoxine, is there a clinical reason?
- Do you provide a batch-level Certificate of Analysis? The CoA should show potency and sterility results for the specific batch you receive.
- How is the dose measured? FDA adverse-event reports cluster around syringe-unit miscounts. A provider who walks you through dose measurement carefully is a meaningful quality signal.
- Where does the bulk active pharmaceutical ingredient come from? Legitimate compounders source from FDA-registered suppliers and can name them.
None of these questions is rude to ask. A compounder confident in its operation answers them in writing and on request.
Frequently asked questions
Is compounded semaglutide the same as Ozempic?
No. Compounded semaglutide and Ozempic share the same active molecule but differ in manufacturer, regulatory status, and formulation. Ozempic is made by Novo Nordisk to FDA-approved specifications. Compounded semaglutide is made by a compounding pharmacy, is not FDA-approved, and typically contains additives such as B12, glycine, or pyridoxine.4
Can you still get compounded semaglutide legally?
After the May 22, 2025 deadline for 503B facilities, neither 503A nor 503B compounders may produce a product that is "essentially a copy" of Ozempic or Wegovy. Some pharmacies still compound semaglutide combined with additives like B12 under a personalization theory, which is contested and subject to active FDA and Novo Nordisk enforcement.1
Will I lose weight with compounded semaglutide?
If the product actually contains the labeled amount of semaglutide, the pharmacologic effect is the same as branded semaglutide, suppressed appetite, slowed gastric emptying, and weight loss over months. The clinical trial evidence is built on branded semaglutide, not compounded versions. Compounded potency varies by pharmacy, which makes outcomes less predictable.5
Why is compounded semaglutide cheaper?
Compounded semaglutide does not carry the research, FDA-approval, and distribution costs Novo Nordisk built into Ozempic and Wegovy pricing. Compounding pharmacies buy bulk active ingredient and prepare finished product at smaller scale, often through telehealth with lean marketing overhead. The price gap is paying for the absence of FDA review of the finished product.
Is compounded semaglutide FDA-approved?
No. Semaglutide as an active ingredient is FDA-approved in Ozempic, Wegovy, and Rybelsus, but compounded finished products are not submitted for FDA approval. Compounding pharmacies operate under a separate regulatory pathway for patient-specific or shortage-related preparation.1
The bottom line
Compounded semaglutide is a category, not a single product. It is any semaglutide injection prepared by a licensed compounding pharmacy rather than manufactured by Novo Nordisk, and the finished product is not FDA-approved. The shortage-era pathway closed after the April 22 and May 22, 2025 deadlines and the April 24, 2025 federal court ruling. What remains is a narrower market of pharmacies compounding semaglutide with additives under a personalization theory that the FDA and Novo Nordisk are actively challenging.
For any specific patient, the question is not whether compounded semaglutide is categorically good or bad. It is whether the specific pharmacy, formulation, salt form, and regulatory posture are transparent enough to evaluate, and whether the pricing gap against branded Ozempic or Wegovy justifies the variability in safety and legal standing. For the compounded picture on the other main GLP-1 molecule, see what is compounded tirzepatide and is it still legal?.
Written By
Rachel Nguyen, MS, RDN
Rachel is a registered dietitian with over a decade of experience in nutrition policy and the economics of health. Her current editorial focus covers GLP-1 medications, obesity medicine, and the intersection of nutrition and pharmaceutical treatment. She holds a Master of Science in Nutrition from the University of North Carolina.
Expert Reviewer
Dr. Kevin Park, PhD
Dr. Park is a nutrition education researcher focused on federal nutrition programs and dietary outcomes. His work has been published in the Journal of School Health and the Journal of the Academy of Nutrition and Dietetics. He reviewed this article's public-health and regulatory framing. Clinical decisions about GLP-1 therapy should be made with a licensed prescriber.
Sources
- US Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. Page content current as of April 1, 2026. Summarizes the February 21, 2025 resolution of the semaglutide shortage and the post-shortage transition windows (503A: April 22, 2025; 503B: May 22, 2025). Also records the April 24, 2025 denial of the preliminary injunction in Outsourcing Facilities Association v. FDA, 4:25-cv-00174 (N.D. Tex.). fda.gov. Retrieved April 20, 2026.
- US Food and Drug Administration. Drugs@FDA approval records. Ozempic (semaglutide injection), NDA 209637, original approval December 5, 2017. Wegovy (semaglutide injection), NDA 215256, original approval June 4, 2021. Drugs@FDA Ozempic record. Drugs@FDA Wegovy record. Retrieved April 20, 2026.
- US Food and Drug Administration. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products. Content current as of July 26, 2024. Describes adverse-event reports "some requiring hospitalization" tied to five-to-20-times dosing errors with compounded semaglutide, including nausea, vomiting, abdominal pain, dehydration, fainting, acute pancreatitis, and gallstones. Also cites compounder use of semaglutide sodium and semaglutide acetate as unapproved salt forms. fda.gov. Retrieved April 20, 2026.
- Novo Nordisk A/S. Compounded "semaglutide" is not FDA-approved. Patient-safety page describing company testing results on market samples of compounded semaglutide, including impurity levels up to 33%, samples with zero measurable active ingredient, and contamination with trace metals, residual solvents, formaldehyde adducts, and BPC-157. Also summarizes Novo Nordisk's civil litigation posture, including the February 9, 2026 lawsuit against Hims & Hers Health, Inc. and a reported 132 federal complaints filed across 40 states. Page last updated February 2026. novomedlink.com. Retrieved April 20, 2026. Manufacturer-published; findings are Novo Nordisk's own and should be weighed accordingly.
- Liu G, Jarema M, Mo M, Stievater T. Navigating compounded semaglutide: what health care providers need to know. American Journal of Managed Care. 2025;31(9):480-484. doi:10.37765/ajmc.2025.89787. PMID 40966636. Narrative review covering the regulatory status, safety, efficacy, and quality-control concerns associated with compounded semaglutide products. pubmed.ncbi.nlm.nih.gov/40966636. Retrieved April 20, 2026.